No black box warning on record for Tagrisso

As of the latest FDA labeling reviewed, Tagrisso (OSIMERTINIB) does not carry a black box warning. Standard warnings and precautions still apply — see the full Tagrisso medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Interstitial Lung Disease (ILD)/Pneumonitis : Monitor for new or worsening pulmonary symptoms indicative of ILD/pneumonitis. For patients receiving TAGRISSO who have not received recent definite platinum-based chemoradiation therapy, permanently discontinue TAGRISSO in patients diagnosed with ILD/Pneumonitis. For patients who received recent definitive platinum-based c

No black box warning on record for Tagrisso

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Interstitial Lung Disease (ILD)/Pneumonitis : Monitor for new or worsening pulmonary symptoms indicative of ILD/pneumonitis. For patients receiving TAGRISSO who have not received recent definite platinum-based chemoradiation therapy, permanently discontinue TAGRISSO in patients diagnosed with ILD/Pneumonitis. For patients who received recent definitive platinum-based c

Tagrisso Black Box Warning

No black box warning on record for Tagrisso

Other warnings & precautions

Tagrisso Black Box Warning

No black box warning on record for Tagrisso

Other warnings & precautions